Literature DB >> 17718120

Immunocytochemistry and fluorescence in situ hybridization in HER-2/neu status in cell block preparations.

Sandra J Shin1, Beiyun Chen, Elizabeth Hyjek, Madeline Vazquez.   

Abstract

OBJECTIVE: Recent studies have validated the use of cytologic materials to determine HER-2/neu status. Good concordance has been shown between results obtained by immunocytochemistry (ICC), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) on cytologic and surgical specimens. However, the utility of cytologic cell block material in determining HER-2/neu status has not been reported and is the subject of this study. STUDY
DESIGN: HER-2/neu status was determined in 25 cases of primary or metastatic breast carcinoma by IHC and FISH. All cases were formalin-fixed, paraffin-embedded (FPPE) cell block preparations. ICC was performed using monoclonal antibodies TAB250 (Zymed) and CB11 (Novacastra Laboratories). FISH analysis was performed using the PathVysion HER-2 probe kit (Vysis, Inc.). Results of ICC and FISH were compared in each case.
RESULTS: Of 25 cases studied, 17 showed no protein overexpression or amplification. Five cases showed protein overexpression and amplification. The remaining 3 cases showed 2+ staining intensity by ICC in 10, 20, and 50% of carcinoma cells, respectively, and all demonstrated lack of amplification.
CONCLUSION: Immunocytochemistry performed on FFPE cell block material is a reliable method for determining HER-2/neu status in cytologic specimens. We recommend routine preparation of FFPE cell block material in instances of suspected primary of metastatic breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17718120     DOI: 10.1159/000325793

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  4 in total

Review 1.  Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades.

Authors:  Shan-Rong Shi; Yan Shi; Clive R Taylor
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

2.  HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES.

Authors:  Marek Malecki
Journal:  Proc S Dak Acad Sci       Date:  2007

3.  OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.

Authors:  Marek Malecki; Raf Malecki
Journal:  Proc S Dak Acad Sci       Date:  2008

4.  Fine-needle aspiration cytology can play a role in neoadjuvant chemotherapy in operable breast cancer.

Authors:  Christian Garbar; Hervé Curé
Journal:  ISRN Oncol       Date:  2013-07-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.